318 related articles for article (PubMed ID: 31240749)
1. Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
Groth D; Perez M; Treat JR; Castelo-Soccio L; Nativ S; Weiss PF; Lapidus S; Perman MJ
Pediatr Dermatol; 2019 Sep; 36(5):613-617. PubMed ID: 31240749
[TBL] [Abstract][Full Text] [Related]
2. Incident psoriasis under treatment with tumor necrosis factor-α inhibitors in juvenile idiopathic arthritis patients-analysis of the BiKeR registry.
Zimmer A; Klein A; Kuemmerle-Deschner JB; Dressler F; Onken N; Brueck N; Fasshauer M; Hospach T; Hufnagel M; Foell D; Horneff G
Rheumatol Int; 2023 Sep; 43(9):1675-1684. PubMed ID: 37291093
[TBL] [Abstract][Full Text] [Related]
3. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
4. Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs.
Baggett K; Brandon TG; Xiao R; Valenzuela Z; Buckley LH; Weiss PF
J Rheumatol; 2022 Aug; 49(8):935-941. PubMed ID: 35428721
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical Psoriasis in Children Receiving Anti-TNFα Treatment for Inflammatory/autoimmune Disease.
Rosenwasser N; Lee D; Sidbury R; Zhao Y
Paediatr Drugs; 2021 Mar; 23(2):131-141. PubMed ID: 33761130
[TBL] [Abstract][Full Text] [Related]
6. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
[TBL] [Abstract][Full Text] [Related]
7. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.
Pastore S; Naviglio S; Canuto A; Lepore L; Martelossi S; Ventura A; Taddio A
Paediatr Drugs; 2018 Apr; 20(2):165-171. PubMed ID: 29214394
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.
Buckley LH; Xiao R; Perman MJ; Grossman AB; Weiss PF
Arthritis Care Res (Hoboken); 2021 Feb; 73(2):215-220. PubMed ID: 31646743
[TBL] [Abstract][Full Text] [Related]
9. Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.
Lee WJ; Lee TA; Suda KJ; Calip GS; Briars L; Schumock GT
Rheumatology (Oxford); 2018 Feb; 57(2):273-282. PubMed ID: 28431162
[TBL] [Abstract][Full Text] [Related]
10. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
11. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
12. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
Davies R; De Cock D; Kearsley-Fleet L; Southwood T; Baildam E; Beresford MW; Foster HE; Thomson W; Ramanan AV; Hyrich KL;
Rheumatology (Oxford); 2020 Jun; 59(6):1391-1397. PubMed ID: 31605484
[TBL] [Abstract][Full Text] [Related]
13. The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study.
Yagiz B; Lermi N; Coskun BN; Dalkilic E; Kiraz S; Erden A; Ertenli I; Duran E; Bilgin E; Yılmaz R; Ateş A; Tufan A; Küçük H; Mercan R; Cinaklı H; Akar S; Yaşar Bilge NŞ; Kaşifoglu T; Türk SM; Gonullu EO; Bes C; Alpay Kanitez N; Emmungil H; Kalyoncu U; Pehlivan Y
Rheumatology (Oxford); 2023 Dec; 62(12):3962-3967. PubMed ID: 37354493
[TBL] [Abstract][Full Text] [Related]
14. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA.
Yue X; Huang B; Hincapie AL; Wigle PR; Li Y; Qiu T; Lovell DJ; Morgan EM; Guo JJ
Rheumatology (Oxford); 2021 Sep; 60(9):4063-4073. PubMed ID: 34469569
[TBL] [Abstract][Full Text] [Related]
16. Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review.
Zhu TH; Nakamura M; Abrouk M; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2016 Oct; 27(5):406-13. PubMed ID: 26837667
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
18. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
19. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
20. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]